294 related articles for article (PubMed ID: 36411768)
1. Long-term results of mycophenolate mofetil
Dalekos GN; Arvaniti P; Gatselis NK; Gabeta S; Samakidou A; Giannoulis G; Rigopoulou E; Koukoulis GK; Zachou K
JHEP Rep; 2022 Dec; 4(12):100601. PubMed ID: 36411768
[TBL] [Abstract][Full Text] [Related]
2. First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients.
Dalekos GN; Arvaniti P; Gatselis NK; Samakidou A; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K
Front Immunol; 2021; 12():798602. PubMed ID: 35087524
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil as second line treatment in autoimmune hepatitis - A retrospective single center analysis.
Kolev M; Diem S; Diem L; Rodrigues SG; Berzigotti A; Stirnimann G; Semmo N
J Transl Autoimmun; 2022; 5():100172. PubMed ID: 36451933
[TBL] [Abstract][Full Text] [Related]
4. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Tushuizen ME; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Baven Pronk MAMC; Beuers U; van der Meer AJ; Gerven NMFV; Sijtsma MGM; van Eijck BC; van IJzendoorn MC; van Herwaarden M; van den Brand FF; Korkmaz KS; van den Berg AP; Guichelaar MMJ; Levens AD; van Hoek B; Drenth JPH;
J Hepatol; 2024 Apr; 80(4):576-585. PubMed ID: 38101756
[TBL] [Abstract][Full Text] [Related]
5. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study.
Jothimani D; Cramp ME; Cross TJ
J Clin Exp Hepatol; 2014 Sep; 4(3):221-5. PubMed ID: 25755564
[TBL] [Abstract][Full Text] [Related]
6. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
[TBL] [Abstract][Full Text] [Related]
7. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial.
Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Pronk MAMCB; Beuers UHW; van der Meer AJ; van Gerven NMF; Sijtsma MGM; Verwer BJ; Gisbertz IAM; Bartelink M; van den Brand FF; Sebib Korkmaz K; van den Berg AP; Guichelaar MMJ; Soufidi K; Levens AD; van Hoek B; Drenth JPH;
Trials; 2022 Dec; 23(1):1012. PubMed ID: 36514163
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital.
Taneja S; Mehtani R; De A; Mitra S; Rathi S; Verma N; Premkumar M; Minz R; Duseja A; Das A; Singh V; Dhiman RK; Chawla YK
J Clin Exp Hepatol; 2023; 13(2):241-251. PubMed ID: 36950480
[TBL] [Abstract][Full Text] [Related]
9. Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series.
Kolev M; Sarbu AC; Möller B; Maurer B; Kollert F; Semmo N
J Transl Autoimmun; 2023; 6():100189. PubMed ID: 36718275
[TBL] [Abstract][Full Text] [Related]
10. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis.
Arvaniti P; Giannoulis G; Gabeta S; Zachou K; Koukoulis GK; Dalekos GN
JHEP Rep; 2020 Aug; 2(4):100123. PubMed ID: 32671332
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
Hennes EM; Oo YH; Schramm C; Denzer U; Buggisch P; Wiegard C; Kanzler S; Schuchmann M; Boecher W; Galle PR; Adams DH; Lohse AW
Am J Gastroenterol; 2008 Dec; 103(12):3063-70. PubMed ID: 18853972
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil.
Liberal R; Gaspar R; Lopes S; Macedo G
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101487. PubMed ID: 32651078
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
[TBL] [Abstract][Full Text] [Related]
15. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis.
Laschtowitz A; Zachou K; Lygoura V; Pape S; Derben F; Jaeckel E; Oller-Moreno S; Weidemann S; Krech T; Piecha F; Schön G; Liebhoff AM; Al Tarrah M; Heneghan M; Drenth JPH; Dalekos G; Taubert R; Lohse AW; Schramm C
JHEP Rep; 2021 Aug; 3(4):100321. PubMed ID: 34381983
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
[TBL] [Abstract][Full Text] [Related]
17. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
[TBL] [Abstract][Full Text] [Related]
18. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes.
Baven-Pronk AM; Coenraad MJ; van Buuren HR; de Man RA; van Erpecum KJ; Lamers MM; Drenth JP; van den Berg AP; Beuers UH; den Ouden J; Koek GH; van Nieuwkerk CM; Bouma G; Brouwer JT; van Hoek B
Aliment Pharmacol Ther; 2011 Aug; 34(3):335-43. PubMed ID: 21668459
[TBL] [Abstract][Full Text] [Related]
19. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
Miehsler W; Reinisch W; Moser G; Gangl A; Vogelsang H
Am J Gastroenterol; 2001 Mar; 96(3):782-7. PubMed ID: 11280551
[TBL] [Abstract][Full Text] [Related]
20. Programmed cell death-1
Gatselis NK; Azariadis K; Lyberopoulou A; Dalekos GN
J Transl Autoimmun; 2021; 4():100126. PubMed ID: 34632357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
